VHL-Associated Optic Nerve Hemangioblastoma Treated with Stereotactic Radiosurgery by Kanno, Hiroshi et al.
Journal of Kidney Cancer and VHL 2018; 5(2): 1–6 
CASE REPORT
VHL-Associated Optic Nerve Hemangioblastoma Treated with 
Stereotactic Radiosurgery
Hiroshi Kanno1,2, Seiki Osano3, Masamichi Shinonaga2
1Department of Neurosurgery, International University of Health and Welfare School of Medicine, Narita, Japan; 2Department of Neurosurgery, 
International University of Health and Welfare Atami Hospital, Atami, Japan; 3Department of Neurosurgery, Shonan Fujisawa Tokushukai 
Hospital, Fujisawa, Japan
Abstract
Central nervous system hemangioblastomas are generally restricted to the cerebellum, spinal cord, and brainstem. Supratentorial 
hemangioblastomas are uncommon, and optic nerve hemangioblastomas are extremely rare, with fewer than 25 reports including 
this case. In this report, we present the case of a 36-year-old woman with von Hippel–Lindau (VHL) disease who presented with 
progressive diminution of vision in the left eye due to a retrobulbar optic nerve hemangioblastoma. The patient had a history of 
cerebellar/spinal hemangioblastomas and pancreatic cysts, and her father and brother were patients with VHL disease. Gadol-
inium-enhanced magnetic resonance imaging showed intraorbital retrobulbar–enhanced mass on the left optic nerve. The optic 
nerve hemangioblastoma was treated with fractionated stereotactic radiosurgery using Novalis. Eighteen months after the ste-
reotactic radiosurgery, the tumor volume decreased although the patient lost vision. This report presents an extremely rare case 
of optic nerve hemangioblastoma, which is the first case treated with stereotactic radiosurgery.
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Introduction
Von Hippel–Lindau (VHL) disease is an autosomal domi-
nant disorder originating from aberrations of the VHL tumor 
suppressor gene that was identified on chromosome 3p25 (1). 
The incidence of VHL is estimated to be 1 in 36,000 to 1 in 
43,000 live births (2, 3, 4). VHL disease is classically associ-
ated with renal cell carcinomas, renal cysts, pancreatic islet 
cell tumors, pheochromocytomas, and endolymphatic sac tu-
mors (5). Central nervous system (CNS) hemangioblastoma 
is the most common VHL-associated lesion, and it is found 
in 70–80% of VHL patients. Hemangioblastoma is a WHO 
grade I benign tumor that does not metastasize to remote 
organs but is associated with significant neurologic morbid-
ity and mortality based on its location and multiplicity (6). 
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In VHL patients, 50–60% of the hemangioblastomas are lo-
cated in the cerebellum, 40–50% in the spinal cord, 10–20% in 
the brain stem, and 2–4% in the pituitary stalk. In the spinal 
cord, 30–50% are located in the thoracic segments, 40–50% in 
the cervical segments, and 10–20% in the lumbar segments (7, 
8). CNS hemangioblastoma is the earliest or the second earli-
est manifestation of VHL patients, and the onset age of CNS 
hemangioblastoma ranges from 7 to 73 years, with the mean 
being 29 years (7, 9). Signs and symptoms vary based on the 
anatomical tumor location, associated edema and cyst, and 
tumor size. Usually, tumors that become symptomatic and re-
quire resection grow faster than the asymptomatic ones (10). 
Most symptoms caused by hemangioblastomas do not arise 
from the solid tumor itself  but from the associated rapidly 
growing cyst or syrinx (11). Therefore, symptoms can occa-
sionally develop rapidly, though usually they develop slowly.
Previous large-scale studies on VHL patients have shown 
that hemangioblastomas have a sporadic growth pattern with 
periods of growth followed by growth arrest, that is, a sal-
tatory growth pattern (12). Patterns of growth vary and are 
categorized as saltatory (70–75% of growing tumors), linear 
(5–7%), or exponential (20–25%). Many tumors will remain 
the same size for several years (12). In a recent study, VHL pa-
tients were found to have a mean of 8.5 tumors/patient (range: 
1–33 tumors/patient) at initial evaluation. Mean tumor devel-
opment was 0.4 new tumors/year and was correlated with age, 
with more frequent development in younger patients (13).
Regarding neuroradiological findings, hemangioblasto-
mas are most often visualized by contrast-enhanced T1-
weighted MRI or contrast-enhanced CT. In post-contrast 
images, the tumor tissue appears as a homogenous bright 
contrast- enhanced mass that clearly stands out from the sur-
rounding tissue. T2-weighted or flair MRI allows excellent 
quantification of edema and peritumoral cysts, which appear 
as high-signal areas (14).
Hemangioblastomas make up nearly 2% of all intracra-
nial tumors and 10% of posterior fossa tumors in adults 
(15, 16). Most hemangioblastomas present as posterior fossa 
masses. Less than 5% of hemangioblastomas present in the 
supratentorial compartment. Hemangioblastomas have been 
rarely seen in the pituitary stalk, optic nerves, and the ventri-
cles (17–19). Herein we report a case of an intraorbital optic 
nerve hemangioblastoma in a patient with VHL, which was 
treated by stereotactic radiosurgery.
Case Report
The patient is a 36-year-old right-handed female with a 
known history of VHL disease. Her 65-year-old father had 
been diagnosed with VHL disease and multiple cerebellar 
hemangioblastomas; her 39-year-old elder brother had also 
been diagnosed with type 1 VHL disease without pheochro-
mocytoma because of a complete deletion of the VHL gene. 
This family pedigree is shown in Figure 1.
At the age of 26, the patient underwent surgical treatment 
for cerebellar hemangioblastoma. She also had a spinal cord 
hemangioblastoma at 11th thoracic vertebra level, a renal 
cyst and multiple pancreatic cysts (Figure 2).
When her father underwent surgical treatment for a cys-
tic cerebellar hemangioblastoma at our hospital (Interna-
tional University of Health and Welfare Atami Hospital), 
she visited our hospital, at the age of 36, because of recently 
developed visual disturbance. Her visual acuity decreased 
gradually and her visual filed became narrow. The visual 
acuities at the first visit to our hospital were 0.1 on the right 
side and sensus luminis on the left side. The examination of 
her left ocular fundus showed a pale papilla (Figure 3).
Magnetic resonance imaging (MRI) of the head showed 
a Gd-enhanced well-circumscribed mass on the left retrob-
ulbar optic nerve in the orbital, and three-dimensional MRI 
showed the tumor enveloped the left optic nerve (Figure 4).
The differential diagnoses for the tumor include optic 
glioma, optic sheath meningioma, optic nerve schwannoma 
and optic nerve hemangioblastoma. Among them, since the 
patient is a VHL patient, the most probable diagnosis was 
thought to be an optic nerve hemangioblastoma. Therefore, 
we made a decision to treat the tumor with stereotactic ra-
diosurgery. At Shonan Fujisawa Tokushukai Hospital, the 
stereotactic radiosurgery was prescribed with the dose being 
39 Gy/13 fractions using Novalis. The planning target vol-
ume was set at 0.7 mL, and D95 (95% of standard irradiation 
volume) was set at 35 Gy/13 fractions. The patient completely 
lost her vision after the radiosurgery. Eighteen months 
after  the radiosurgery, the tumor volume slightly decreased 
(Figure 5), but her vision has been still lost. The consent to 






Figure 1. The family pedigree of the patient. (A) The pa-
tient’s father is a 65-year-old VHL patient. (B) The patient’s 
mother is a 64-year-old non-VHL woman with malignant 
lymphoma and colon cancer. (C) The patient’s brother is a 
39-year-old VHL patient. (D) The current VHL patient is a 
36-year-old woman with an optic nerve hemangioblastoma.
VHL-associated optic nerve hemangioblastoma
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Discussion
VHL disease is an autosomal dominant disorder that fre-
quently develops CNS hemangioblastomas. Patients with a 
complete deletion of the VHL gene have been found to have 
a decreased incidence of retinal hemangioblastoma when 
compared with patients with a missense mutation (20). This 
patient did not have a retinal hemangioblastoma but had an 
optic nerve hemangioblastoma.
The origin of stromal cell, that is, neoplastic cell of heman-
gioblastoma, has been suggested to be an embryonic heman-
gioblast cell which is a common precursor for hematopoietic 
and endothelial cells (21–23). During normal embryonic de-
velopment, Scl is only transiently expressed at the embryonic 
hemangioblast cells in the diencephalon containing optic 
nerve, metencephalon, and spinal cord. In addition, Scl pro-
tein expression is shown in CNS hemangioblastoma in retina, 
spinal cord, brainstem, and cerebellum. Diencephalon con-
tains optic nerve, and therefore, hemangioblastoma possibly 
originates from optic nerve (24–26). The striking topograph-
ical analogy between embryonic Scl expression and the sites 
of tumor development may, therefore, help explain the selec-
tive topography of CNS hemangioblastoma.
The differential diagnosis for a solitary optic nerve tumor 
includes an optic nerve sheath meningioma and an optic 
glioma. Meningioma is commonly associated with neu-




Figure 2. Magnetic resonance imaging of the patient. (A and B) Gadolinium (Gd)-enhanced T1-weighted image of cerebellum 
when the patient was 26 years old. The patient had multiple cerebellar hemangioblastomas. (C) Gd-enhanced T1-weighted image 
of the lower thoracic cord. A small hemangioblatoma with a syrinx is shown. (D) T2-weighted image of the lower thoracic cord. 
(E) T1-weighted image of the abdomen. A renal cyst and multiple pancreatic cysts are shown.
(A) (B)
Figure 3. Optic fundi before radiosurgery. (A) Left healthy side. (B) Right lesion side.
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associated with neurofibromatosis type 1 (28), while heman-
gioblastoma is commonly associated with the VHL disease. 
The patient had the VHL disease with a germline mutation 
of the VHL gene. This fact strongly suggested that this optic 
nerve tumor is a hemangioblastoma.
Until now, 20 cases of optic nerve hemangioblastoma in-
cluding this present case have been reported in the English 
literature (29–40). Fourteen of the 20 cases (70%) were as-
sociated with VHL. The ages of the 20 patients ranged from 
15 to 64 years, with a mean being 34.8 years. There have been 
13 females and 7 males diagnosed with this lesion. Nine of 
the patients had intraorbital masses, 5 patients had intracra-
nial tumors, and 6 patients had a combination of intracranial 
and intraorbital masses. Meyerle et al. reported 9 cases re-
viewing the clinical course of retrobulbar hemangioblasto-
mas including 4 optic nerve hemangioblastomas (35). In their 
series, 4 of 300 VHL patients developed optic nerve heman-
gioblastomas. From these data, the incidence of optic nerve 
(A) (B) (C)
(D)
Figure 4. Magnetic resonance images before radiosurgery. (A) Gadolinium (Gd)-enhanced T1-weighted image, sagittal. 
(B)  Gd-enhanced T1-weighted image, axial. (C) Gd-enhanced T1-weighted image, coronal. Yellow arrows show the tumor. 
(D) Three-dimensional planning MRI for radiosurgery. The light blue color indicates the tumor enveloping the optic nerve.
(A) (B) (C)
Figure 5. Gadolinium-enhanced magnetic resonance images at 18 months after the stereotactic radiosurgery. (A) Sagittal image. 
(B) Axial image. (C) Coronal image.
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hemangioblastomas is estimated as 1.3% in a population with 
VHL disease.
As complete surgical resection is curative, surgical resec-
tion is recommended as the first-line treatment for CNS 
hemangioblastomas. As an alternative or second-line treat-
ment, stereotactic radiosurgery for hemangioblastomas has 
been indicated, especially for incompletely resected, residual, 
multiple, recurrent, and surgically inaccessible tumors that 
have anatomy unfavorable for surgical resection. Stereotactic 
radiosurgery is also indicated for patients with medical mor-
bidities that make invasive procedures too risky and for VHL 
patients who have had multiple surgical resections. Stereotac-
tic radiosurgery is able to target a small hemangioblastoma 
and offers the advantage of having a lower morbidity com-
pared with surgical resection (41). In the past 20 years, ste-
reotactic radiosurgery has been used as a minimally invasive 
adjuvant or salvage option for patients with hemangioblasto-
mas. Before the era of stereotactic radiosurgery, management 
of residual or surgically inaccessible hemangioblastomas re-
quired the use of conventionally fractionated radiotherapy. 
Conventional radiotherapy has the disadvantage of expos-
ing the surrounding normal tissue to irradiation and has the 
advantage of less adverse injury to neural tissues than non-
fractionated stereotactic radiosurgery (42, 43). This patient 
was treated with 13 fractionated stereotactic radiosurgeries. 
However, despite a reduction in tumor volume, the patient 
lost her vision after the radiosurgery.
Conclusion
Differential diagnosis for a solitary optic nerve tumor usually 
includes an optic nerve sheath meningioma, an optic schwan-
noma, and an optic glioma. However, in patients with VHL 
disease, hemangioblastoma should remain in the differential 
diagnosis of optic nerve tumors. The current report describes 
the first known case of an optic nerve hemangioblastoma 
treated with stereotactic radiosurgery. Optic nerve heman-
gioblastomas are extremely rare, and fractionated stereotactic 
radiosurgery can be occasionally indicated for treatment, when 
it is difficult to preserve vision with surgical resection. Al-
though the approach resulted in tumor shrinkage, the patient 
lost eye sight. It is not clear whether the vision loss followed a 
natural course, as the patient presented with a visual acuity of 
0.1, or radiosurgery somehow accelerated the process.
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